These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559 [TBL] [Abstract][Full Text] [Related]
8. The effects of OKT4A monoclonal antibody on cellular immunity of nonhuman primate renal allograft recipients. Wee SL; Stroka DM; Preffer FI; Jolliffe LK; Colvin RB; Cosimi AB Transplantation; 1992 Mar; 53(3):501-7. PubMed ID: 1532265 [TBL] [Abstract][Full Text] [Related]
9. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Kovarik J; Wolf P; Cisterne JM; Mourad G; Lebranchu Y; Lang P; Bourbigot B; Cantarovich D; Girault D; Gerbeau C; Schmidt AG; Soulillou JP Transplantation; 1997 Dec; 64(12):1701-5. PubMed ID: 9422405 [TBL] [Abstract][Full Text] [Related]
10. Excellent outcome with a calcium channel blocker-supplemented immunosuppressive regimen in cadaveric renal transplantation. A potential strategy to avoid antibody induction protocols. Suthanthiran M; Haschemeyer RH; Riggio RR; Adubor C; Friedman GS; Cheigh JS; Wang JC; Fotino M; Stubenbord WT; Saal SD Transplantation; 1993 May; 55(5):1008-13. PubMed ID: 8497873 [TBL] [Abstract][Full Text] [Related]
16. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group. Thistlethwaite JR; Nashan B; Hall M; Chodoff L; Lin TH Transplantation; 2000 Sep; 70(5):784-90. PubMed ID: 11003358 [TBL] [Abstract][Full Text] [Related]
17. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Kahan BD; Rajagopalan PR; Hall M Transplantation; 1999 Jan; 67(2):276-84. PubMed ID: 10075594 [TBL] [Abstract][Full Text] [Related]
18. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Hong JC; Kahan BD Transplantation; 2001 May; 71(9):1320-8. PubMed ID: 11397971 [TBL] [Abstract][Full Text] [Related]
19. Use of OKT4A (a murine monoclonal anti-CD4 antibody) in human organ transplantation: initial clinical experience. Norman DJ; Bennett WM; Cobanoglu A; Hershberger R; Hosenpud JD; Meyer MM; Misiti J; Ott G; Ratkovec R; Shihab F Transplant Proc; 1993 Feb; 25(1 Pt 1):802-3. PubMed ID: 8438490 [No Abstract] [Full Text] [Related]